Pulmonx Corp (LUNG): debt financing — Pulmonx Q4 revenue $15.4M (+13% YoY); draws $20M debt; FY23 guidance $63-65M

Pulmonx Corp

2022-FY EPS reported -$1.59 revenue$53,662,000

Q4 2022 revenue $15.4M, up 13% YoY; U.S. revenue $9.5M (+30% YoY).
Full year 2022 revenue $53.7M, up 11% YoY; net loss $58.9M ($1.59/share).
FY2023 revenue guidance $63-65M; gross margin 73-74%; operating expenses $112-114M.
Drew $20M from CIBC loan on Feb 21, 2023; floating rate at Prime +1%.
Added 17 new U.S. treatment centers in Q4, total 278; preparing for Japan launch.

item 2.02 item 2.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Pulmonx Corp incurred credit facility of $20.0 million with Canadian Imperial Bank of Commerce at 1.0% above the Wall Street Journal Prime Rate.

Instrument: credit facility
Principal: $20.0 million
Counterparty: Canadian Imperial Bank of Commerce
Rate: 1.0% above the Wall Street Journal Prime Rate
Event: incurrence

Exact text from the filing

On February 21, 2023, the Company exercised its option to draw $20.0 million available under a Loan and Security Agreement with Canadian Imperial Bank of Commerce (“CIBC”).

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Pulmonx Corp reported the full year of 2022 results: revenue $53.7 million, net income $58.9 million, EPS $1.59 per share.

Period: the full year of 2022
Revenue: $53.7 million
Net income: $58.9 million
EPS: $1.59 per share
Result: reported results

Exact text from the filing

invasive treatments for lung disease, today reported financial results for the fourth quarter and full year of 2022 ended December 31, 2022. Recent Highlights • Delivered $53.7 million in worldwide revenue for the full year of 2022 • Achieved record worldwide revenue of $15.4 million for the fourth quarter of 2022, a 13% increase over the same period last year

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Pulmonx Corp reported the full year 2023 results: revenue $63 million to $65 million. Guidance initiated.

Period: the full year 2023
Revenue: $63 million to $65 million
Guidance: initiated
Result: guidance update

Exact text from the filing

Pulmonx expects revenue for the full year 2023 to be in the range of $63 million to $65 million.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Pulmonx Corp reported the fourth quarter of 2022 results: revenue $15.4 million, net income $14.3 million, EPS $0.38 per share.

Period: the fourth quarter of 2022
Revenue: $15.4 million
Net income: $14.3 million
EPS: $0.38 per share
Result: reported results

Exact text from the filing

and full year of 2022 ended December 31, 2022. Recent Highlights • Delivered $53.7 million in worldwide revenue for the full year of 2022 • Achieved record worldwide revenue of $15.4 million for the fourth quarter of 2022, a 13% increase over the same period last year and an increase of 18% in constant currency • Set a new record of $32.5 million and $9.5 million in

View on SEC.gov

Browse all debt financings →

Pulmonx Corp filing history →

Source: SEC EDGAR

accession 0001127537-23-000005

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.